Search clinical trials for: PD1 Monoclonal Antibody

Total 6865 results

Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

Cancer | Solid Tumor
University of Melbourne
Johns Hopkins University; Oregon Health and Science University; University of... and other collaborators

Completed

HIV Persistence in Lymph Node and Peripheral Blood (HIV-PRADA)

HIV-1-infection

Australia
Merck Sharp & Dohme LLC

Terminated

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Multiple Myeloma
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Completed

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

B-cell Lymphoma

China
Zhejiang University
Bioray Laboratories

Completed

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Castrate-Resistant Prostate Cancer

China
Lei Li

Unknown

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Chemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 Antibody

China
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy (FIL_Tisle-HL)

Hodgkin Lymphoma

Italy
Xuanwu Hospital, Beijing

Recruiting

A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy

Immunotherapy | ADR

China
Yale University
National Cancer Institute (NCI); Arcus Biosciences, Inc.

Recruiting

AB154 Combined With AB122 for Recurrent Glioblastoma

Glioblastoma

United States
Second Affiliated Hospital of Guangzhou Medical...
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.; Hunan Zhaotai Yongren Medical...

Recruiting

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Cancer | Lung Cancer | Immunotherapy | CAR-T Cell

China
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Melanoma | Lymphoma | Solid Tumor | Classical Hodgkin Lymphoma | Microsatellite-instability-high Solid Tumor

France, Germany, Italy, Netherlands, Sweden, United Kingdom, Brazil, Israel, Korea, Republic of, United States
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Non-Small-Cell Lung Carcinoma

Japan
Symphogen A/S

Active, not recruiting

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Solid Tumor | Metastatic Cancer

United States, Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Hodgkin Lymphoma

United States, Brazil, Colombia, Czechia, France, Germany, Greece, Guatemala, Italy, Korea, Republic of, Mexico, Netherlands, Slovakia, South Africa, Spain, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Hodgkin Lymphoma
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Carcinoma, Non-Small-Cell Lung

United States, Ireland, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

Carcinoma, Hepatocellular

Korea, Republic of, China, Hong Kong, Malaysia, Taiwan
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms

Brazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
Checkpoint Therapeutics, Inc.

Terminated

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO)

Metastatic Non-squamous Non Small Cell Lung Cancer

Peru, Russian Federation, South Africa, New Zealand, Georgia, Thailand, Brazil, Malaysia
Merck Sharp & Dohme LLC

Completed

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Neoplasms | Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Highlight Therapeutics
Pivotal S.L.

Completed

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Cancer

Spain
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Advanced Solid Tumors

United States, Singapore, Italy, United Kingdom
Ikena Oncology
Bristol-Myers Squibb

Withdrawn

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head Cancer | Neck Cancer | Head Cancer Neck | Neck Carcinoma

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma (PREDIMEL)

Malignant Melanoma
CStone Pharmaceuticals

Completed

A Study of CS1002 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

Hong Kong, Australia
Fundacion para la Investigacion Biomedica del Hospital...

Recruiting

Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

Lung Cancer

Spain
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Pfizer

Terminated

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Gastrointestinal Tumors | Esophageal Adenocarcinomas | Colorectal Adenocarcinomas | Gastric Adenocarcinomas

United States, Australia, Japan
University of Vienna

Recruiting

Evaluation and Importance of the PD-1/PD-L1 and the IL-10/IL-10R Axis in Malignant and Benign Pleural Effusions - a Pilot Study

Pleural Effusion

Austria
Augusta University

Terminated

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

Prostatic Neoplasms

United States
Shanghai Zhongshan Hospital
RenJi Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaborators

Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma | Lenvatinib | PD1 Antibody | Gemox Chemotherapy

China
Xinqiao Hospital of Chongqing
TCRCure Biopharma Ltd.

Recruiting

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC

Head and Neck Squamous Cell Carcinoma

China
Ou Bai, MD/PHD
Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University

Recruiting

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Angioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified

China
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Fudan University

Completed

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Cancer

China
Bioray Laboratories
Wuhan Union Hospital, China; Zhejiang University; Institute of Hematology ＆ Blood...

Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Assiut University

Unknown

Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain

Chronic Pain

Egypt
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Anti-PD1 Antibody

China
SYZ Cell Therapy Co..
Peking University Cancer Hospital & Institute

Unknown

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

Advanced Gastric Cancer

China

Search clinical trials for: PD1 Monoclonal Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations